Callio Therapeutics

Callio Therapeutics is a startup based in the United States. Its most recent tracked round is Series A. Brouky classifies it under Software & Developer Tools. Brouky records 2 investors associated with the company.

Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, developing next-generation, multi-payload ADCs that feature differentiated payload and linker technologies to enable targeted delivery of multi agents to tumor cells.